US and German-based HMNC Brain Health (HMNC Holding GmbH), a clinical stage biopharma company pioneering precision psychiatry, has raised nearly $14 million (EUR 14.3 million) in the closing of the first of two expected funding series, bringing the total capital raised to date to over $41 million (EUR 42.3 million.) The second closing of this round would be completed by the end of March 2023.
Additional funding came from existing investors such as Carsten Maschmeyer, the Jahr Group and Guntard Gutmann as well as new investors, namely former Deutsche Bank (NYSE:DB) CEO Dr. Josef Ackermann, Real Madrid’s Toni Kroos, Dermapharm’s Wilhelm Beier and Hans Kompernaß (Hans Kompernaß GmbH).
